Skip to main content
. 2023 Oct 20;42(11):1241–1251. doi: 10.1200/JCO.23.01891

FIG 3.

FIG 3.

Forest plot on the basis of PFS. ABCP, atezolizumab plus bevacizumab, paclitaxel, and carboplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; ITT, intention-to-treat; PC, pemetrexed plus carboplatin or cisplatin; PFS, progression-free survival.